Akari Therapeutics, Plc has entered a strategic research collaboration with Whitehawk Therapeutics to evaluate the potential of combining Akari's proprietary PH1 spliceosome-modulating payload technology with Whitehawk's topoisomerase I inhibitor (TOP1i) antibody drug conjugate (ADC) platform. The partnership aims to advance ADC innovation by assessing dual payload compatibility and synergies through a series of focused preclinical studies. Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari Therapeutics, highlighted the increasing industry focus on differentiated ADC payload technologies, noting that recent strategic transactions continue to underscore the growing value being placed on novel payload innovation.

Under the agreement, Akari will lead the design, execution, and evaluation of the research activities. The initial collaboration includes multiple preclinical workstreams intended to generate data that will guide future development decisions and potentially broader collaboration opportunities between the two companies. The planned preclinical studies are designed to assess dual payload synergy and generate data that could support future development opportunities for next generation ADCs.

Collaboration Objectives

The primary goal of the collaboration is to explore the broader potential of Akari's PH1 payload technology to combine with current classes of ADC payloads. The studies are designed to validate PH1's differentiated mechanism and support the development of a first-in-class dual payload technology for novel ADCs targeting cancer. The discussion also explored the scientific rationale for combining differentiated ADC payload technologies, how dual payload approaches may expand therapeutic opportunities beyond traditional single payload ADCs, and why management believes collaborations such as Whitehawk further validate the broad applicability of Akari's PH1 platform across future oncology programs.

Executive Perspectives

Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari Therapeutics, emphasized the significance of the collaboration. "This collaboration marks an important first step in exploring the broader potential of our PH1 payload technology to combine in unique ways with current classes of ADC payloads across the field to advance ADC innovation and impact," he stated. "As the ADC field continues to evolve and industry interest shifts toward differentiated payload innovation, we believe Akari is uniquely positioned to help shape the next generation of ADCs through our novel spliceosome modulating platform and strategic collaborations such as this one."

Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics, highlighted the strategic fit. "Beyond our existing portfolio, we see dual-payload approaches as a potential next opportunity to expand the therapeutic potential of our ADC platform," Lennon said.

Key Technologies

The collaboration is expected to commence immediately, with interim data updates anticipated as studies progress. Both companies will jointly review the resulting data to determine whether the findings support broader development discussions.

Maxim Group analyst Jason McCarthy upgraded Akari Therapeutics from Hold to Buy and announced a $30 price target. The adjustment signals a revised outlook on the company's stock performance.

The upgrade moves the stock from a neutral stance to a buy recommendation. The $30 price target provides a specific valuation benchmark for investors.